Zura Bio Limited (ZURA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Zura Bio Limited (ZURA) closed at USD 4.28 on 2026-10-15, a change of +13.2 % over the past year, with a market capitalization of USD 371.82M.

Zura Bio Limited recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Zura Bio Limited key figures

Previous close

USD 4.28 (2026-10-15)

1-year change

+13.2 %

Market cap

USD 371.82M

Enterprise value

USD 166.68M

P/E ratio (trailing)

-3.46

P/E ratio (forward)

-5.62

EPS (trailing)

-1.12

EPS (forward)

-0.69

PEG ratio

n/a

Price to book

1.88

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.44

Employees

40

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Zura Bio Limited

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Zura Bio Limited and compare it with other stocks.